GSK2578215A is a potent and selective inhibitor of LRRK2 (leucine-rich repeat kinase 2), a protein kinase implicated in Parkinson’s disease. It is primarily used in research settings to study the role of LRRK2 in neurodegenerative pathways. Due to its high selectivity and cellular permeability, it enables scientists to probe LRRK2-related signaling mechanisms and assess the therapeutic potential of its inhibition. The compound is widely applied in preclinical models to evaluate effects on neuroinflammation, mitochondrial function, and neuronal survival. Its use supports drug discovery efforts aimed at developing disease-modifying treatments for Parkinson’s and other LRRK2-associated disorders.